Innate Pharma Sa Class A · EURONEXT:IPH

Innate Pharma Sa Class A — Investor Day (July 2016)

91 slides from Innate Pharma Sa Class A's investor day presentation, Jul 13, 2016

  1. Slide 1: G;>6;@93>736;@9 A@5A>A9K5A?B3@K 8A5GE76A@;@@3F7

    G;>6;@93>736;@9 A@5A>A9K5A?B3@K 8A5GE76A@;@@3F7 ;??G@;FK (FE;FE &LCP

  2. Slide 2: Disclaimer

    '*/*$''#!&+,,%&, 0?@J ;F:LD<EK ?8J 9<<E GI<G8I<; 9P %EE8K< N8II8EKP FI LE;<IK8B@E> <OGI<JJ FI @DGC@<; @J ,?8ID8 / K?< ^FDG8EP_ JFC<CP =FI K?< D8;< 8J KF 8E; EF I<C@8E:< J?FLC; 9< GC8:<; FE GLIGFJ<J F= 8 GI<J<EK8K@FE KF @EM<JKFIJ K?< =8@IE<JJ 8::LI8:P :FDGC<K<E<JJ FI :FE:<IE@E> K?< FDG8EP 0?@J ;F:LD<

  3. Slide 3: Speakers

    %&%&,,% $<IMX 8K?<I@E< ,@<II< &XIZD< .%((5 )+1'$!%%. + %+* 0%+((%!. ,? ) ) ) ,? ( F =FLE;<I ,E7I<FBE<A4A68 ;<89&87<64? ;<898I8?BC@8AG (99<68E (99<68E "@@HABG86;, &BI8G<F 38?G<4 +" )9<M8E )4FG8HE&8E<8HK 86>@4A BH?G8E &BE:4A,G4A?8L 'BI4EG<F I8AG<F ,4A:FG4G 58EE@J *@:FC8@ )8I:<C )+.!( 3#0)** .+6!*3!%#

  4. Slide 4: Innate Pharma overview

    -!$!&$!&'&'$'1'%(&1'-+'& !&&,!%%-&!,1 <998E8AG<4G874A7'BI8? ` ,@FE<<I F=K?<@EE8K<@DDLE<JPJK<D8E;*':<CC9@FCF>P ,6<8A68 <A "@@HAB (A6B?B:L ` $@>?CP GIF;L:K@M< . FI>8E@Q8K@FE ` :C@E@:8CJK8>< :8E;@;8K<J8;;I<JJ@E>EFM<CK8I><KJ )BEG9B?<BB9<EFG <A ?4FF @E:CL;@E> KNF ;@==<I<EK@8K<;:?<:BGF@EK@E?@9@KFIJ AG<5B7

  5. Slide 5: Strategy and development model

    +,*,1 ,''% -$$1!&,*, !'( *%'%(&1 + 6B??45BE4G<BA ?B54? B 78I8?BC@8AG 4A7 "A !BHF88I8?BC@8AG B@@8E6<4?<M4G<BA&BA4?<MH@45 ); "" B9 ")! ` 0<JK@E>@EDLCK@GC<@E;@:8K@FEJ ` .<K8@E =LCC;<M<CFGD<EK8E; ` ,LIJL<J@E>C< 8><EK:FD9@E8K@FE K?<I8G@<J D8IB<K@E>I@>?KJKF%,$ ` <E<=@K =IFDC8K<JK8><;<M<CFGD<EK8E;D8IB<K@E>

  6. Slide 6: Pipeline

    .$'(!& *'&!.*+!!&,!'1('*,'$!' /!, &'.$% &!+%+',!'& )+( +& -+ - "'"-"(' ,- !8@8;C<01 5GF7%K7>A;6$7G=7?;3 +;@9>7397@F (:3E7!! $;57@E76FA #!* $ D;EFA>%K7DE +CG;44 +A>;63@6:7?3FA>A9;53>FG?ADE %G>F;B>75A?4;@3F;A@E (:3E7!!!FD;3>E ">=0;8HC<01 +A>;63@6:7?3FA>A9;53>FG?ADE +;@9>7397@F3@6 A67H7>AB?7@FI;F: &# (

  7. Slide 7: Stock and financial information

    + *(!,$ .*'(##!.()$+' 08??64C<G4?<M87J<G;64F; 64F;8DH<I4?8AGF 4A79<A4A6<4? <AFGEH@8AGFB9 R @<??<BA4GG;88A7B9* ` (@JK<; FE!LIFE<OK %,+@E*FM<D9<I !LIFE<OK,8I@J". \ %,$ ` /KF:BC@HL@;@KP@E M<I8>< ;8@CPKI8;@E>MFCLD< D FLKJK8E;@E> J?8I<J =LCCP;@CLK<; ` E8CPJK :FM<I8>< IP8E#8IE@<I %EM<JK /<:LI@K@<J *FMF*FI

  8. Slide 8: Immuno-oncology section

    !&&,( *%N+ * +,*,1 & ((*' +!& !%%-&' '&'$'1

  9. Slide 9: Checkpoint inhibitors unmet need

    !%%-&''&'$'1 *.'$-,!'&!&&* ,*,%&, #$' %$#)(.$#% ` %+:8EC<8;KFGIF=FLE;8E;;LI89C<I<JGFEJ<J@EJL9J<KJF=G8K@<EKJ !OG<:K<;KF@DG8:K8CC@E;@:8K@FEJ 8CCC@E<JF=KI<8KD<EKJ ` (<;9P:?<:BGF@EK@E?@9@KFIJ K?8K^I<C<8J<K?<9I8B<_FE0:<CCJ ` LKD8EPG8K@<EKJ=8@CKFI<JGFE;FGK@D8CCP S EFE I<JGFE;<IJ@E?<8;E<:B I<E8C CLE> 9I<8J

  10. Slide 10: Checkpoint inhibitors mechanism

    !&&, ( *%N+ ($,'*% $*#)') )*"$' (% . $$()# #)*'! !!' !!( #*-+ -&(*+ '$ '$ ` ,IFM@;<I8G@; =@IJK C@E<;<=<EJ< ` @I<:KCP B@CC KLDFIJ 8E; M@ILJ @E=<:K<; :<CCJ '$ ` ,IF;L:<:PKFB@E<J< > %"* PK?8K8I< '$ :I@K@:8C=FI8;8GK@M<0:<CCI<JGFEJ<J ` %DGFIK8EK IFC< @E :FEKIFCC@E>D<K8JK8J@J (397

  11. Slide 11: NK cell section

    &#$$+*'&,*'$$1,!.,!&&!& !!,'*1 *(,'*+ %% !! ,(*!-',#('+ $"+ '$ '+F : &" ! !% *" , %% (397

  12. Slide 12: NK cells

    , *(-,!(',&,!$'&# $$+*.$!&%$ ')')+!)$# ` *':<CCJ:8E@DGIFM<JLIM@M8C@E )( :LK<)P<CF@;(<LB<D@8G8K@<EKJ I<:<@M@E> ?8GCF @;<EK@:8CJK<D:<CC KI8EJGC8EK8K@FE 9986GF 4E87HE45?84A7 F498 /LIM@M8C .<C8GJ< '$46G<I4G<BA '$<A;<5<G<BA $;00.82.:*3%,2.5,. 56:916=5 $;00.82 .:*3366- (397

  13. Slide 13: NK cell targeting

    *'%$$',*&+($&,,!'&,'*- ('(* ,# ', %%+ %+, ! '#)$# ' ! #$ '#)$# !!# -;8E4C8HG<6G4E:8G<A: E8DH<E874 C4A$"+% @5 %<E<?H@45 (397

  14. Slide 14: NK cell mechanisms

    &#$$ &,!&*-&,!'&+ O #0BC@0;2GB>B>F828BG (DAH;6773D>K5A@FDA>4K6;D75F>K =;>>;@9FG?ADE O GB>:8=4?@>3C2B8>= +F;?G>3F7363BF;H7;??G@7 D7EBA@E74KE75D7F;@95KFA=;@7E 7 9 %+F:3F EF;?G>3F7E 67@6D;F;557>>E3@6 !& 3@6!$ F:3FEF;?G>3F7E,57>>E O '>;4A8=<4<>@G@4A?>=A4A @F;4A6K67B7@67@F5KFAFAJ;5;FK !@5D73E;@97H;67@57F

  15. Slide 15: NK cell checkpoint treatment

    '-*+,*,11'&( (HEFGE4G8:L9BE) ABA (HEFGE4G8:L9BEC4G<8AGFJ<G; BEC4EG<4? E8FCBA78EFJ<G; ABA <A9?4@87GH@BEF <A9?4@87C;8ABGLC8 @JG<:@=@:JK?8KKI@>><I*':<CCJ FD9@E8K@FEKI<8KD<EKN@K? KFB@CC8E;KFGIFM@;<8E *':?<:BGF@EKD9J @EE8K<9FFJK <> #) /" %"* KF8:K@M8K<8E;I<:IL@K J8E; D9JK8I><K@E>JLGGI<JJ@M< 0:<CCJ D@:IF<

  16. Slide 16: NK cell biology

    !*&,&#+-+,+0(*++!.*+*(,'*+ J# '%)$'(K#!($-%'((.)!!( '$ '$ $"+ '$ '$ '$ "'!""-"(' -"/-"(' ` + '$ '$ ` ` " ` ` '$ AG< $"+ AG< '$ AG< '$ (397

  17. Slide 17: Lirilumab

    !&&, ( *%N+ (!($!& )')# %$#)(#""*#$$#$!$. '$68?? $"+ '$ '$C -H@BE 4AG<:8A $"+% &" -H@BE68?? "@@HA868?? (397

  18. Slide 18: Lirilumab

    $!*!$-%!*+,!&$++&,!#!* % !#( )$'()$!".'( (&* '$68?? !8@8;C<010=B8 ' $"+ '$ '$C -H@BE 4AG<:8A $"+% &" -H@BE68?? "@@HA868?? (397

  19. Slide 19: Activating receptor and ligand

    $!*!$-% !+!*+,!&$++ #!* #('!&,!& !!,'* "#(" $ )$# 0,(%0,# "*'-% + :K@M8K@E> '%. I<:<GKFI :K@M8K@E> $( C@>8E; -&(* %% /)* ++#'" -&(* %% (*&% %%'(, /)* ++#'" ,#.,#'"%#"' /)* ++#'",#.,#'" ,#.,#'"%#"' %#"' ($#%% #%% ($#%% (-,(#&&-'#,0 (397

  20. Slide 20: NK cell killing

    *,!'&$ '* $!*! M &!.''%',*!$+ # !!( !! )*"$'( ')!.#!%) !!( # :8;;8=6 4=70=243 1G '1;>2:034 # 24;; # 34@8D43 #63@8D4A 8=5;0<<0B8>=0=3! AB8<C;0B4A ) 24;;A ) 24;; :8;;8=6 4=70=243 1G 0=B8)! >@0=B8% ) 24;; (397

  21. Slide 21: Combination rationale

    &# #('!&,*(,'*+!& !!, "$#()')$## ((.( ` /@D@C8ICP 9P8EK@ 8E; 8EK@ !#". @J <E?8E:<;9P:FD9@E@E>N@K?8EK@ '%. FI8EK@ *'# $6++259.:*3 % 769:.8 %63*.:3 % 769:.8 618: .:*3 366- 5:.85*3 -*:* (397

  22. Slide 22: Monalizumab

    %'&$!2-%!( !*+,!&$++&,!&# % $+!$%"#) # $"'!/)$# '"#) ,) ()'/# '$68?? $"+ ">=0;8HC<010=B8# '$ '$C -H@BE 4AG<:8A $"+% &" -H@BE68?? "@@HA868?? (397

  23. Slide 23: NKG2A inhibitory receptor

    %'&$!2-%!+ !*+,!&$++ &# #('!&, !& !!,'* "#("$ )$# ` *'# @J 8E @E?@9@KFIP I<:<GKFI FE KLDFI @E=@CKI8K@E> 0 :<CC 8E; *' :<CCJ ` ,I<M<EKJ @EK<I8:K@FE N@K? $( ! DFC<:LC<J KF GFK<EK@8K< *' :<CCJ 8E; 0 :<CCJ 8EK@ KLDFI 8:K@M@KP @F;&# '$ 68?? -H@BE 68?? 7 &# $ :K@M8K@E> :K@M8K@E> I<:<GKFI C@>8E; $ % &# ,*

  24. Slide 24: NKG2A cell expression

    #!*&&# 0(*++!'& $#'#)(*()($# !!( >AA6&#57>>E8DA?8AGD:73>F:K 6A@ADEA@7 ;@735:B3@7> EF3;@76 8AD#!*3@6&# $"+ '$ 55*:.#1*84* (397

  25. Slide 25: NKG2A expression in tumors

    ,-%'*!&!$,*,!&&#$$%'+,$10(*++&# # $)##*$#)!!(#)*"$'( ::LDLC8K@FEF=*'# %E;L:<;<OGI<JJ@FEF=*'#FE *':<CCJ@EJ@;<KLDFIJ KLDFI@E=@CKI8K@E> 0:<CCJ (LE>:8I:@EFD8 <IM@:8C :8E:<I ?BB7'$! "AGE4GH@BE4?'$ ?BB7-68?? "AGE4GH@BE4?-68?? #3*:656<* .:*3 *5,.8$.9 %1.; .:*3 *5,.8$.9 (397

  26. Slide 26: Cancer expression

    %&1 ,-%'*+ '.*0(*++ $, $!&'&# ` $( ! LGI<>LC8K<; FE8 N@;< M8I@<KP F= KLDFI KPG<J $* +M8I@8E !E;FD<KI@LD FCFI<:K8C <IM@O (LE> +<JFG?8>LJ (( ` .<JKI@:K<; <OGI<JJ@FEFEEFID8CK@JJL<J ` C@E@:8C ;<M<CFGD<EK GC8E @E=FID<; 9P<OGI<JJ@FEF=$( ! !% 8KCE8FF<BABA64E6<AB@468??F 0LDFI )8E68AG4:8 B9 C4G<8AGF %$J:FI<

  27. Slide 27: Blocking antibody in cancer cells

    $ 0(*++!'&'& *!&'% $$+ & $1%( '1,+ ## )*"$' 4 &8@5E4ABHF FG4<A<A: BA?L@C;B6LG8F 4 4 AG< !% N: @? 4 &8@5E4ABHF 6LGBC?4F@<6 FG4<A<A: BA 64E6<AB@4 68??F 4 4 @": "N: @? (397

  28. Slide 28: Receptor recognition in humans

    %'&$!2-%,*,+&# #('!&,'&&#$$+ &,$$+ ` *'#I<:F>E@Q<$( !@E?LD8EJ8E;-8 @ED@:< '$68?? -H@BE68?? -68?? '$68??4A7-68??<A;<5<G<BA5L'$ 6G<I4G<BA5L'$ 5?B6>478 (397

  29. Slide 29: Expression on macrophages and monocytes

    ) 4 !+!&-'& $$+ 1!& & ,*&*,%&,!&%! &0 1 %! 3 "438C< # -8 8E; , ( <OGI<JJ@FE 8CJF LGI<>LC8K<; FE KLDFI @E=@CKI8K@E> D8:IFG?8><J 8E; DFEF:PK<J %63*.:*3 $ 769:.8 (397

  30. Slide 30: Monalizumab preclinical data

    &,!&# (#!#) .%##)$#%'(#$# !!( AG< '$ "FBGLC86BAGEB? AG< '$ '$68??78C?8G87 -H@BE IB?H@8 @@ )+ )+ )+ + + + 4LF 4LF 4LF EK@ *'# D9 KI<8KD<EK @E;L:<; *' :<CC D<;@8K<; 8EK@ KLDFI <==@:8:P @E 8 GIFG?PC8:K@: J<KK@E> )@:< N<I< I8E;FD@Q<; N?<E KLDFI MFCLD<J DD E >IFLG 8E; KI<8K<; K@D<J FE:< 8 N<<B N@K? % 8EK

  31. Slide 31: Preclinical mouse results

    !&*+*)-&1'&# ,$$+!&%! *+!+,&,,'( (, /1$'# - ?L@C;B6LG8F " <) AG )@:< KI<8K<; N@K? @E;@:8K<; D9J T> @G K@D<J <M<IP ;8PJ N<I< J8:I@=@:<; FE ;8PJ FI 8=K<I KLDFI <E>I8=KD<EK 0 :<CCJ N<I< :?8I8:K<I@Q<; 9P =CFN :PKFD<KIP )<8EJ / F= *'# , 8DFE> 0 :<CCJ , , * *'# *' :<CCJ 8DFE> *' :<CCJ N<I< EFK DF;@=@<; 9P

  32. Slide 32: Preclinical survival data

    '%!&&# &( $'#!&*++'%($, *+('&+*,& +-*.!.$!&%! ,HEI<I4? 4LF )@:< N<I< I8E;FD@Q<; N?<E KLDFI MFCLD<J DD E D@:< >IFLG 8E; KI<8K<; K@D<J <M<IP ;8PJ N@K? % 8EK@ *'# T> @M 8EK@ , T> @G FI 8EK@ *'# 8E; 8EK@ , D9 ,FFC F= @E;@M@;L8C KLDFI MFCLD<J F= KNF @E;<G<E;<EK <OG<I@D<EKJ '8GC8E )<@<I JLIM@M8C (F> .8EB

  33. Slide 33: Monalizumab

    !( &,!%! '$68?? $"+ '$ '$C % 0=B8" -H@BE 4AG<:8A $"+% &" -H@BE68?? "@@HA868?? (397

  34. Slide 34: Mechanism of action

    !( !+!*+,!&$++&,!%! % ` )%8E;)%8I<GFCPDFIG?@:DFC<:LC<JF=K<E<OGI<JJ<;FEKI8EJ=FID<; 8E;JKI<JJ<;:<CCJ ` )% 8I<C@>8E;J=FI*'# I<:<GKFIJFE *':<CCJ8E; 0:<CCJ 83=4G 20@28=><0 ' =3><4B@8C< -H@BE ?B64?<M4G<BA )BF<G<I84F8FA '@;E<P (8I><@EK<JK@E< /@>DF@; :FCFE !E;FD<KI@LD "4;0=><0 0?PIF@; #C8E; )7G@>83 ;0=3 ;C=

  35. Slide 35: Monalizumab tumor data

    !( -%&!2 &,!%! *! "#(" $)$# -H@BE68?? '$68?? -68?? &46EBC;4:8 '$4A7-68??<A;<5<G<BA5L 6;EBA<6 H4?@86;4A<F@B946G<BA GH@BE4AG<:8AG4E:8G<A:4A7 8KCBFHE8 GB&" <@@HAB@B7H?4G<BA (397

  36. Slide 36: Prostate cancer data

    !( #++$ . # (%$#)#$*( "$*( )*"$' "$! 99<646L<A@BHF8@B78?B9CEBFG4G8 ")! @B": 46HE8F-+&) &"@<689EB@ 64A68E-+&) &" CEBFG4G864A68E5LE8FGBE<A:;<FGB?B:LB9CEBFG4G8 :?4A74A7<A7H6<A:'$68??<A9<?GE4G<BA ) BAGEB? ")! @B" *FID8C LI<; 3<CC ;@==<I<EK@8K<; ,FFICP ;@==<I<EK@8K<; !EAFKB7 5A@FDA> *' @E=@CKI8K@FE !( ?A

  37. Slide 37: Cell engager

    !+(!!&#$$&*+ '$68?? $"+ '$ 8A?428582 # 24;; 4=6064@A '$C -H@BE 4AG<:8A $"+% &" -H@BE68?? "@@HA868?? (397

  38. Slide 38: Innate platform

    !&&,N+ !+(!! &#$$ &*+ ),$"$'##$+)$#( ` ,G<@H?4G8F '$68??F<AFG847B9- 68??F %EE8K< ?8J@;<EK@=@<;EFM<C=@IJK @E :C8JJ8>FE@JK8EK@ *'G D9J K?8KKI@>><I *' :<CCJJG<:@=@:8CCP *':<CC8:K@M8K@FE?8JEFKC<;KF:PKFB@E<JKFIDJ !OG<:K@DGIFM<;9<E<=@K I@JB GIF=@C<8KKI8:K@M< =FI;<M<CFGD<EK@EJFC@; KLDFIJ ` '8J @B?86H?4E78F

  39. Slide 39: Activation of NK cells

    !&&,N+ !+(!!&#&*($,'*% )''## !!#)'$*# ? %># D9 *'G :K@M8K@FE F= *' :<CCJ -H@BE68?? -H@BE 4AG<:8A @JG<:@=@:*':<CC!E>8><I '$C <FC86<9<6 '$68??A:4:8E :K@M8K@FEF= *33 *' :<CCJ *'G (397

  40. Slide 40: Cell data

    / 1 ''+&#B'*,*!*!&&#$$+ ` %E=LJ@FEF=*':<CCJ?8JEFKI<JLCK<;@E (,<A&%6BEE8?4G8FJ<G;'$C :PKFB@E<JKFIDJ@EG8K@<EKJN@K? 8KCE8FF<BA ?<D8KFCF>@:8CFIJFC@; KLDFIJ ` *'G@J8GFK<EK8:K@M8K@FEI<:<GKFI FE*' :<CCJ (I8E4?? ,HEI<I4? ` *'G<OGI<JJ@FEC<M<C :8E:FII<C8K< N@K? :8E:<IG8K@<EKJLIM@M8C <> @E )( ` *'G @J<OGI<JJ<;

  41. Slide 41: Patient data

    / 1,*,&#(!&+,' )*"$'#!)')# # !!( $)#$,#'*!) *)')## ? $<8CK?P ;FEFIJ9CFF; E ,8K@<EKJ 9CFF;E %EKI8KLDFI8C E *FEKLDFI8C;@JK8EK CLE>E ;50*8,2564* #3*:656<* .:*3*5,.8 $.9.*8,1 8.*9:*5,.8 *4.992.8 .:*3 325 5<.9: (397

  42. Slide 42: Data results

    &#( +-**',(*'%',,-%'*#!$$!& 4L +4=<68??F"/ +847 BHGFHEI<I4? 4L 4L 4L (397

  43. Slide 43: Platform strategy

    (*'(*!,*1&#(!+(!!($,'*% ` /K@DLC8K<J*':<CCJ@EJK<8;F=0:<CCJ KKI8:K@M<=FI;<M<CFGD<EK@EJFC@;:8E:<I@E;@:8K@FEJ @E:CL;@E>EFE @E=C8D<; ` *FM<C DFC<:LC8I ;<J@>E ,8K<EK<;;<J@>E M<IJ8K@C<DF;LC8I=FID8K ` 3<8I<9LC;@E>8G@G<C@E<F=GIFGI@<K8IP9@ JG<:@=@:GIF;L:K:8E;@;8K<J ` *FE <O:CLJ@M<*'GK<:?EFCF>PG8IKE<IJ?@GJ C@

  44. Slide 44: Section

    &'+!& (, /1 )')# ""*#$(*%%'((+ )*"$' "'$#+'$#"#) '$68?? $"+ '$ '$C -H@BE 4AG<:8A )% %0B7E0G $"+% &" -H@BE68?? "@@HA868?? (397

  45. Slide 45: Mechanism on regulatory and immune cells

    &'+!&(, /1&,!&,! )')# ""*#$(*%%'((+)*"$'"'$#+'$#"#) -68?? (G;8E <@@HA868?? -H@BE FCE847<A: =B8 =B8 '$68?? =B8 -H@BE 78C?8G<BA 8A7E<G<668?? BE-68?? -) 8;<EFJ@E<KI@G?FJG?8K< &) 8;<EFJ@E< DFEFG?FJG?8K< ` 8E; 8I<<EQPD<J<OGI<JJ<; FEI<>LC8KFIP0:<CCJ @DDLE<:<CCJ 8E;KLDFI :<CCJ@EK?<KLDFID@:IF<EM@IFED<EK ,IF

  46. Slide 46: Monalizumab data

    !( '()#!((#) #)$. ` %,$;@JGC8PJJ@E>C<8><EK8:K@M@KP !H@4A<M87@5<A;<5<GFGH@BE:EBJG;<AK8AB:8A8<6GH@BE@B78? -H@BE:EBJG; )8E68AG FHEI<I4? -H@BE IB?H@8 @@ 8PJ $L8 $L% ;02.8.:*3 $ 769:.8 (397

  47. Slide 47: Combination with checkpoint blockers

    !( %$)#)!$'$"#)$#,)#')')"#)( ` ;@JILGK@FE ;I@M<J 8EK@KLDFI@DDLE<I<JGFEJ<J <@K?<I8CFE<FI@E :FD9@E8K@FEN@K?, :?<:BGF@EK9CF:B<IJ 8EK@9F;@<J8E;@DDLEF><E@: :?<DFK?<I8GP JL>><JK@E>9IF8;;<M<CFGD<EKGFK<EK@8C -E84G@8AGJ<G;4AG< )4A7 BK4?<C?4G<A <A$(@<68?847FGB+ -H@BE:EBJG; ,HEI<I4? 0-@<68 >B@<68 *72.88..:*3 $

  48. Slide 48: Humanized antibody

    !( &,! ` "@IJK @E :C8JJ ?LD8E@Q<; 8EK@ D9 N@K? ?@>? 8==@E@KP 8E; JG<:@=@:@KP =FI 9CF:BJ 0,8J< 8:K@M@KP "% ,"*(& 9FK? FE KLDFI :<CCJ 8E; @DDLE< :<CCJ ` % ,",& ?LD8E@Q<; 8EK@ D9 J@>E@=@:8EKCP @E?@9@KJ GFJ@K@M< KLDFI >IFNK? ` IF8; ;<M<CFGD<EK GFK<EK@8C JL>><JK<; 9P <OG<I@D<EKJ @E BEF:B FLK D@:< @E:CL;@

  49. Slide 49: Targeting tumor microenvironment

    &,!&/ #('!&, !& !!,'* (*'*%,*,!& , ,-%'*%!*'&.!*'&%&, -68?? (G;8E <@@HA868?? -H@BE FCE847<A: =B8 =B8 '$68?? =B8 -H@BE 78C?8G<BA 8A7E<G<668?? BE-68?? ` 08I><K@E> D8P9CF:BKLDFI:<CCD<K8JK8J@J9PI<;L:@E>K?< ><E<I8K@FEF=@DDLEFJLGGI<JJ@M< 8;<EFJ@E< ` G8E<CF=8EK@9F;@<J N<I<;@J:FM<I<;K?8K @E?@9@K =LE:K@FE9P

  50. Slide 50: Strategy summary

    !&&,( *%N+*+,*,1& ((*' + !& !%%-&''&'$'1 "@IJK @E :C8JJ:?<:BGF@EK8EK@9F;@<JK8I><K@E>*':<CCI<:<GKFIJ *FM<C8EK@ *'G9@JG<:@=@:GC8K=FIDK<:?EFCF>P @I<:K@E>*':<CCJKFB@CCKLDFIJ 08I><K@E>@DDLEF JLGGI<JJ@FE@EKLDFID@:IF<EM@IFED<EKKFLEC<8J? :PKFKFO@:*'8E;0:<CCJ 38554@4=B80B430??@>02710A43>=# 24;;A (397

  51. Slide 51: Section

    '&'!& $!&!$ (*'*%+

  52. Slide 52: Section

    $!*!$-% !*+,!&$++ &,!#!*% $!&+,' *!+,'$%1*++)-!

  53. Slide 53: Elderly patients trial

    ( +!,*!$/!, 1*!'% &,!#!*!( ` !C;<ICP)(G8K@<EKJ@E:FDGC<K<I<D@JJ@FE8=K<I@E;L:K@FE8E;:FEJFC@;8K@FE KI<8KD<EK D8@EK<E8E:<J<KK@E> ` ,?8J<%;FJ< <J:8C8K@FE@E:CL;@E>G8K@<EKJ@E=@IJK . 8E; JKL;P <OK<EJ@FE @E:CL;@E> 8;;@K@FE8CG8K@<EKJ@E. FJ<J I8E><;=IFD KF D> B> \ "LCC'%.J8KLI8K@FE 8K ;FJ<JbD> B> ` #FF;KFC<I8E

  54. Slide 54: Section

    ( +!,*!$/!, 1*!'% &,!#!*!( #*)$#$# !!)+)$#"' '( '.>.:*3366- (397

  55. Slide 55: Survival data

    ( +!,*!$/!, 1*!'% &,!#!*!( )'#(#!#! $*)$"'!))$ '$*%#. ` /L>><JK<;8:FII<C8K@FE9<KN<<E=LCCI<:<GKFIF::LG8E:P8E;<==@:8:P ` C@E@:8CFLK:FD<+/,"/:FDG8I<;=8MFI89CPKFI<GFIKJ@E:FDG8I89C< G8K@<EKGFGLC8K@FE BF8 ' ),@BAG;F (,@BAG;F D> B> D> B> $. % , M8CL< +/+M<I8CC/LIM@M8C ,"/,IF>I<JJ@FE"I<</LIM@M8C +/8E;,"/8E8

  56. Slide 56: Phase I trial

    $!*!$-%( +! ` /@E>C< 8><EK,?8J<%N@K?8M8I@<KPF=?<D8KFCF>@:8E;JFC@;KLDFIJ /CFNCPGIF>I<JJ@M<FIJK89C<;@J<8J<FI@E:FDGC<K<I<JGFEJ< F<JEFK8CCFN8JJ<JJD<EKF= KLDFI I<JGFEJ< ` ,I@D8IP<E;GF@EKJ8=<KPJ<:FE;8IP<E;GF@EKJ,' , ` G8K@<EKJKI<8K<; 8K;FJ<C<M<CJ=IFD D> B>KF D> B> ` 3<CCKFC<I8K<; EF;FJ<C@D@K@E>KFO@:@KP D8

  57. Slide 57: Survival rate in elderly patients

    !#!*('+!,!'&!&!&-,%1$'!$-#%! ()'$# "!# #!'!.%)#)( ` P<8IJLIM@M8CI8K<@E<C;<ICP )@40B<4=B?0@0386< G8K@<EKJN@K?)(@JKF %0B84=BA G %0B84=BA G I I ` *F:LII<EKJK8E;8I;F=:8I<=FI <C;<ICPG8K@<EKJ@EGFJK =3C2B8>=274<>B74@0?G @E;L:K@FEJ<KK@E> ' 'I ` %EK<EJ@M<;<M<CFGD<EK<==FIK@E >=A>;830B8>= B74= >=A>;830B8>= )(=

  58. Slide 58: Enrollment and results

    !#!* ( +!! ,*!$ $*!!#%!$$#)'$!! '#$"/)'! # "! ` 08I><K<EIFCCD<EK:FDGC<K<;@E&LCP G8K@<EKJ ` 8K8FEC<LB<D@8=I<<JLIM@M8C("/<OG<:K<;$ ` +E<8:K@M<8IDJKFGG<;@E)8I:? LGFE /)I<:FDD<E;8K@FE /) :FEJ@;<I<;K?8KKI<8KD<EK@EK?<JKFGG<;8ID:FLC;EFK9<JLG<I@FIKF GC8:<9F 0?<I<N8JEF:FE:<IEN@K? KFC<I8E:< . )@E@D@Q8K@FE (@I

  59. Slide 59: Combination study

    $!&!$(*'*%+/!, $!*!$-% #' %)#)()$'+ !'!*" %( %)#)( #)$# ())*( 3F3A@$+ !==@'%. *3@6A?;L76 5GF7%K7>A;6$7G=7?;3 %A@AF:7D3BK 7JB75F76 (:3E7!! %3;@F7@3@57E7FF;@9 (:3E7!I;F:6AE7 +7>75F76EA>;6FG?ADE @DA>>?7@F5>AE7 &;HA>G?34 7E53>3F;A@3@6 %$&+$!+ & FA5A?B>7F;A@ 5A:ADF7JB3@E;A@ (:3E7!I;F:6AE7 +7>75F76:7?3FA>

  60. Slide 60: Section

    %'&$!2-% !*+,!&$++ &,!&# % '.$'(%&,& '%%*!$!2,!'& *%&,/!, +,*2&

  61. Slide 61: Tumor expression

    %&1 ,-%'*+ '.*0(*++ $, $!&'&# ` $( ! LGI<>LC8K<; FE8 N@;< M8I@<KP F= KLDFI KPG<J $* +M8I@8E !E;FD<KI@LD FCFI<:K8C <IM@O (LE> +<JFG?8>LJ (( ` .<JKI@:K<; <OGI<JJ@FEFEEFID8CK@JJL<J ` C@E@:8C ;<M<CFGD<EK GC8E @E=FID<; 9P<OGI<JJ@FEF=$( ! !% 8KCE8FF<BABA64E6<AB@468??F 0LDFI )8E68AG4:8 B9 C4G<8AGF %$J:FI<

  62. Slide 62: Phase trial

    !&!,!$$!&!$.$'(%&,($&/!, %'&$!2-% !#!+!$%"#)%!##$'".-%'(($#$! %( %)#)( #)$# ())*( !$!/)$# 736&75= +F3DF7675 %A@AF:7D3BK (:3E7! !! GDAB7 &7A36<GH3@FE7FF;@9 (:3E7! !!I;F:6AE7 K@75A>A9;53> +F3DF76+7BF %A@AF:7D3BK -BFA 3@363 7E53>3F;A@ 53@57DE;@5> AH3D;3@ (:3E7! !!I;F:6AE7 :DA@;5$K?B:A5KF;5 +F3DF76'5F !

  63. Slide 63: Section

    !( !*+,!&$++ &,!#!*$ 1,','0! % !& '-+ .$'(%&,

  64. Slide 64: T-cell lymphoma

    -,&'-+,$$$1%( '%,$ $'%#((,)"!# ` 0( @J8>IFLGF=I8I< 8E;?<K<IF><E<FLJ:LK8E<FLJ CPDG?FD8JF=0 :<CCJ N@K? GFFIGIF>EFJ@J8E;=<NK?<I8G<LK@:FGK@FEJ8K8;M8E:<; JK8><J S G8K@<EKJ@E!18E;1/ 0?< DFJK:FDDFE0( JL9KPG<J8I<)P:FJ@J =LE>F@;<J )"8E;/XQ8IPJPE;IFD<// +M<I8CC JLIM@M8C;<G<E;J@EG8IKFE;@J<8J< JL9KPG< ` *FJK8E;

  65. Slide 65: Expression data

    #!*$ !++(!!$$10(*++'&-,&'-+ & !*-$,!&,$ $$+ ` %II<JG<:K@M<CP F=;@J<8J<>I8;< 8E;FEDFJKJL9KPG<J SF=8CC 0( !OGI<JJ@FE@JDFI<GIFD@E<EK@E/XQ8IPJPE;IFD< KI8EJ=FID<;DP:FJ@J=LE>F@;<J 8E; (, ((JL9KPG<=IFD KF F=G8K@<EKJ ` .<JKI@:K<;<OGI<JJ@FEFEEFID8CK@JJL<J )4G<8AGF5<BCF<8FFG4<A87J<G;"AA4G8QF4AG< $"+%@5 ,,CG :

  66. Slide 66: Trial results

    ( + !+,-1' !( ()')# ` FJ< <J:8C8K@FE:F?FIK<OG8EJ@FEJKL;P@E'%. (G8K@<EKJ FJ< <J:8C8K@FE ;FJ<C<M<CJF=I<G<8K<;8;D@E@JKI8K@FEJF=%,$ F?FIK<OG8EJ@FE:F?FIKJF= G8K@<EKJ<8:?@E//8E;K)" ` 0(JL9KPG<JN@K?K?<DFJK=I<HL<EK'%. (<OGI<JJ@FE ` $@>?<JKLED<KD<;@:8CE<<; ` !18E;1/ @EMFCM@E>I<=<II8C<OG<IK:<EK<IJ ` FDGC<K@FE

  67. Slide 67: Dose escalation

    +-%%*1 ` LE@HL< ;@==<I<EK@8K<;8GGIF8:?98J<;FE*':<CCJ ` IF8;G@G<C@E<F==@IJK @E :C8JJ:?<:BGF@EK 8EK@9F;@<JN@K?;@M<IJ<)+J ` ;I<JJ@E>?<K<IF><EFLJG8K@<EKGFGLC8K@FE N@K?8EK@9F;@<JK8I><K@E>;@JK@E:K :?<:BGF@EKJ8E;;@M<IJ<*' 8E;0:<CCGFGLC8K@FEJ /@E>C< 8><EK8E;:FD9@E8K@FEK?<I8GP@E9IF8;I8E><F=:8E:<I@E;@:8K@FEJ

  68. Slide 68: Summary and strategy

    -!$!&$!&'&'$'1 '%(&1'-+ '& !&&,!%%-&!,1 ` @==<I<EK@8K<;8E;EFM<CJ:@<E:<@E@DDLEF FE:FCF>P ` ,FIK=FC@FF==@IJK @E :C8JJ8EK@9F;@<J ` ,8IKE<IJ?@GJN@K?C<8;@E>@DDLEF FE:FCF>P:FDG8E@<J "AI8FG@8AG ,H@@4EL ` /KI8K<>PKF9<:FD<8=LCCP @EK<>I8K<; 9@FG?8ID8 :FDG8EP ` /KIFE>=@E8E:@8CGFJ@K@FE8E;D8E8><D<EKK<8DKF<O<:LK<

  69. Slide 69: Investor relations contact

    !&.+,'* *$,!'&+ (8LI< $XCVE<)<I:@<I /I @I<:KFI %EM<JKFII<C8K@FEJ @EM<JKFIJ@EE8K< G?8ID8 :FD 0<C

  70. Slide 70: Contents

    ((&!0 ADBAD3F7835FE ( 3F3A@&#57>>E ( 3F3A@ >;D;>G?34 ( 3F3A@ ?A@3>;LG?34 ( 3F7A@!( ( 3F3A@AF:7D3EE7FE ( ,75:@A>A9;7E (

  71. Slide 71: Financial statements

    !&&!$ ! $! ,+ ()'$###!%$()$# 284E8A787868@58E "A G;BHF4A7 8HEBF "+, +8I8AH84A7BG;8E<A6B@8 .<J<8I:?8E;;<M<CFGD<EK<OG<EJ<J #<E<I8C8E;8;D@E@JKI8K@M<<OG<EJ<J '8GBC8E4G<A:8KC8AF8F (C8E4G<A:<A6B@8 ?BFF "@E8E:@8C@E:FD< <OG<EJ< E<K '8G <A6B@8 ?BFF 3<@>?K<;8M<I8><ELD9<IF=J?8I<J@EK?FLJ8E;J *<K @E:FD< CFJJ G<I

  72. Slide 72: Appendix

    &#$$+ ((&!0

  73. Slide 73: Appendix

    ,-%'*!%%-&'+-*.!$$&!&.'$.+''(*,!'& ,/&!&&,&(,!.!%%-&$$+ LEE +C;8E;/:?I<@9<I %DDLE@KP (397

  74. Slide 74: Immunity and tumor

    !&-+!'&'&#$$+&(*.&,*$(+!&$*$1 %$(,!&,+!&'%($,*%!++!'& %#($#(*#)#*"'($ '"(")# !!( ;8:2.:*3 325*5,.8$.9 (397

  75. Slide 75: Control of tumor cells

    !&+'%%'$+&#$$+'&,*'$,-%'**'/, /!, '-,&'*,$$+ '$68??6BAGEB?B96B?BA64A68E?<I8E @8G4FG4F<F 7E<I8A 5L4A<AA4G8<@@HA8 6<E6H<G<A@<68 ` *CIG@E=C8DD8JFD< @E;L:<;%( GIFDFK< D8KLI8K@FE8E;KLDFIB@CC@E>9P*':<CCJ ` 0LDFI:FEKIFC;<G<E;JFE*' 9LKEFK0FI:<CCJ ;7*;312,625..:*344;52:> (397

  76. Slide 76: Innate Pharma

    &*!%%-&', *(1((*' +''+,!&&#$$+ )') '%)$'($## !!( EK@ R)/ :BA<FG @ "AA4G8);4E@4 K8I><K@E> 9@JG<:@=@:J R ==@D<; ;86>CB<AG<A;<5<GBEF <FC86<9<6F (@I@CLD89R %,$ )/ %( R <CJ@FE LGB><A8 )FE8C@QLD89 R %,$ 6* ! %( R.F:?< AG<5B7L "% 9HF<BACEBG8<AF <FC86<9<6F .*':<CCJR *8*'N<JK <CP8; *'G K8I><K@E> 9@JG<:@=@:J

  77. Slide 77: Lirilumab

    LIRILUMAB APPENDIX

  78. Slide 78: Mechanism

    &# #('!&,*(,'*+!& !!, ')*-" . ###.!'!*" %% !! ,(*!-',#('+ + " *" , %% -*7:.-/864 618: .:*3366- (397

  79. Slide 79: Monalizumab

    MONALIZUMAB APPENDIX

  80. Slide 80: Example of lung adenocarcinoma

    $0(*++!'&'&*+(''*(*'&'+!+!&+'% &*+ 0?<<O8DGC<F=CLE>8;<EF:8I:@EFD8 $( !ELD9<I (FN $@>? '*5-.8;80.:*3"5,6:*80.: (397

  81. Slide 81: IPH4102, IPH4301, IPH52

    IPH4102 IPH4301 IPH52 APPENDIX

  82. Slide 82: Humanized antibody study

    !( !+!*+,!&$++1,','0!!,1!&-!&&,!'1 %$)#) #))*"$')+). # "$!($+#)! ` $LD8E@Q<;:PKFKFO@:%># +#" $"+%,K8AB:E49G@B78? HGB?B:BHFJ<G;-%C4G<8AG68??F *"%* ('()%**",&% -H@BE4?IB?H@8@@ %,$ "FBGLC86BAGEB? I@KLO@D89 ,OM4EL68??F 8C<DKLQLD89 ")! N: GJ<684J88>K -E4G<B 4LFCBFG+4=< $"+%68??<A=86G<BA '$9986GBEF -%GH@B

  83. Slide 83: Analysis of tissue panel

    (*, 1*'! $& !+ , '&$1 &'*%$,!++- /!, +(!!'&+!+,&,%! +,!&!& %HA: FDH4@BHF 'BE@4?%HA: 'BE@4? CE<@4EL 'BE@4? )4E4G;LEB<7 68?? 64E6<AB@4 C4E8A6;L@4 5EBA6;HF B?BA ?4A7 AG< &" &( "FBGLC8 BAGEB? ,C86<9<6 'B FG4<A<A: 'BA FC86<9<6 'BA FC86<9<6 ,C86<9<6 %$8E8CPJ@JF=" 8GGIFM<; K@JJL<G8E<C;FEFIJGIK@JJL< "",!J8D

  84. Slide 84: Ongoing results

    !( (',&, 1*+,!&(*!%*1 -%&&#$$+ +4=< &" <A7<A: %LF<F % '8BCF8<01 A>BG?4 2>=B@>; 4BCF8<01 ,) =IFD ?<8CK?P ;FEFIJ \ ! 0 (397

  85. Slide 85: Expression in cancers

    !( #$+!%$)#)#) #)$. ` @J<OGI<JJ<;@EJ<M<I8C?LD8E:8E:<IJ @E:CL;@E>?<8;E<:B CLE> :<IM@:8C <JFG?8><8C J8I:FD8 C@M<I B@;E<P G8E:I<8K@: K?PIF@; <E;FD<KI@8C KLDFIJ 8JN<CC8J@ECPDG?FD88E;D<C8EFD8 !847A86> 8EI<K %<I8E )4A6E84F ,B9GG<FFH8 ,DH4@BHF8??4E6<AB@4 ,DH4@BHF68??64E6<AB@4 !8C4GB68??H?4E?<I8E$ 78AB64E6<

  86. Slide 86: Appendix

    , &'$'!+ ((&!0

  87. Slide 87: Pipeline overview

    !+(!!&,!'!+ $$"#!+!).%%'$+!$ !#.)$ - "- +- -4A75 18A6BE @:8A &46EB:8A<6F 99<@87 /:"2 ":'EF9J @E $FC<J /:"2 K8E;<D /:"2 ?P9I@; /:"2 ?P9I@; )FEFM8C<EK )FEFM8C<EK )FEFM8C<EK @M8C<EK 0:<CC<E>8><I GGIFM<;@E(( ,?8J<%)( ,?8J<*$( (( #G *'<E>8><I ,?8J<%JFC@; KLDFIJ ,?8J<%%$( (397

  88. Slide 88: Clinical data

    $!&,-%'% !+(!!,$$&* +!)$# $ (% $#%) *) ,)($" )$-).((*( $2+.8*.:*3 "5,6&*80.:9 *5-&1.8*7> (397

  89. Slide 89: Contact

    &#B !+(!!+ %$)#) !!#.%'"'.!$$# !!($!).$#$'( (%)"*')' -%'(($# ,C86<9<6 %LF<F EK@ 9@E;@E>;FD8@EN8J;<I@M<;=IFD 9C@E8KLDFD89 %0! (397

  90. Slide 90: Patient diagnosis

    &#( !+(!!+ !&-#!$$!&'$$$+,+1 -,'$''-+(,!&,&#$$+ /)&FIF/5?4FGF - GB@BAG;F +47<B ;8@B BA'$68??F / E<GHK<@45 / / ,)J ,)J ((G8K@<EK8K ((G8K@<EK ;@8>EFJ@J 8=K<IKI<8KD<EK HGB?B:BHF F8GG<A: / /)&FIF/5?4FGF - BA'$68??F (( 9C8JK *':<CC '$C * @JG<:@=@:*':<CC!E>8><I (397

  91. Slide 91: Closing slide

    +-**',!+(!! )+)$#$"$*(# !!( ,HEEB:4G8<FC86<9<6 '$ 68??A:4:8E AG< @B'$C4AG<5B7L .8A@ :<CC &BHF<9<87 I8EF<BAB94E4GAG< DFLJ< @BHF8'$C4AG<5B7L *':<CC @B'$C !==<:KFIJ )FLJ<*' :<CCJ GLI@=@<; =IFD G% KI<8K<; D@:< 08I><KJ .8A@ C89<CC<; N@K? I ! 0 (397

Innate Pharma — Investor Day (July 2016) on 6ix